On page 1465, there is an error in Figure 6C. During figure assembly, the wrong image was inserted in the panel on the right in the row labeled CD31. The corresponding author has created a replacement figure with the correct image. This error does not affect the major conclusions of the study. The corrected Figure 6 is shown below.
In vivo efficacy of IC488743 treatment of human MM xenografts in SCID mice. (A) Mice injected with 5 × 106 LB cells were treated orally twice a day with control vehicle (●), and IC488743 10 mg/kg ( □ ) or 30 mg/kg (○). Mean tumor volume was calculated as in “Murine xenograft models of human MM.” Error bars represent SD. (B) Representative whole-body images from a mouse treated for 12 days with control vehicle (top panel) or IC488743 (30 mg/kg; bottom panel). (C) Tumors harvested from IC488743 (30 mg/kg) treated mouse (right panel) and control mouse (left panel) were subjected to immunohistochemical analysis using CD31 and P-AKT Abs. CD31 and P-AKT positive cells are dark brown. (D) Mice were treated with IC488743 10 mg/kg (hyphenated line), 30 mg/kg (dotted line), or control vehicle (solid line). Survival was evaluated from the first day of treatment until death using Kaplan-Meier curves. (E) Tumor tissues were harvested from mice treated with control vehicle or IC488743 (30 mg/kg). Protein levels of phosphorylated of PDK-1 and AKT (Ser473) were determined by Western blotting of cell lysates. Actin was used as a loading control. (F) Growth of INA-6 cells engrafted in human bone chips in SCID mice was monitored by serial serum measurements of shuIL-6R. Mice were treated with IC488743 10 mg/kg ( □ ), 30 mg/kg ( △ ), or control vehicle (●), and shuIL-6R levels were determined weekly by ELISA. Error bars represent SD.
In vivo efficacy of IC488743 treatment of human MM xenografts in SCID mice. (A) Mice injected with 5 × 106 LB cells were treated orally twice a day with control vehicle (●), and IC488743 10 mg/kg ( □ ) or 30 mg/kg (○). Mean tumor volume was calculated as in “Murine xenograft models of human MM.” Error bars represent SD. (B) Representative whole-body images from a mouse treated for 12 days with control vehicle (top panel) or IC488743 (30 mg/kg; bottom panel). (C) Tumors harvested from IC488743 (30 mg/kg) treated mouse (right panel) and control mouse (left panel) were subjected to immunohistochemical analysis using CD31 and P-AKT Abs. CD31 and P-AKT positive cells are dark brown. (D) Mice were treated with IC488743 10 mg/kg (hyphenated line), 30 mg/kg (dotted line), or control vehicle (solid line). Survival was evaluated from the first day of treatment until death using Kaplan-Meier curves. (E) Tumor tissues were harvested from mice treated with control vehicle or IC488743 (30 mg/kg). Protein levels of phosphorylated of PDK-1 and AKT (Ser473) were determined by Western blotting of cell lysates. Actin was used as a loading control. (F) Growth of INA-6 cells engrafted in human bone chips in SCID mice was monitored by serial serum measurements of shuIL-6R. Mice were treated with IC488743 10 mg/kg ( □ ), 30 mg/kg ( △ ), or control vehicle (●), and shuIL-6R levels were determined weekly by ELISA. Error bars represent SD.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal